Overland Park, Kansas 66209

  • Hereditary Breast and Ovarian Cancer


PROGECT is a registry for patients with Triple Negative breast cancer (TNBC) or patients who have an identified germline mutations (such as a mutation on the BRCA1 or BRCA2 genes).

Study summary:

This study is being done to collect cancer-related information from patients with triple negative breast cancer and patients with hereditary genetic mutations. This information will help us better understand the link between genetic changes and cancer outcome in patients with triple negative breast cancer.


Inclusion criteria include: Triple Negative Breast Cancer - ER/PR <10% and HER negative per current ASCO/CAP guidelines - Stages I-IV - Any age at diagnosis - Patient must be within 5 years of diagnosis - Eligible regardless of genetic testing status - Genetic testing recommended for patients meeting NCCN and Medicare guidelines AND/OR Germline mutation Carriers - Patients with deleterious or uncertain mutations in HBOC genes (BRCA, PTEN, P53, -PALB2 etc) are eligible regardless of type/site of cancer - Healthy patients harboring mutations also eligible - There is no time limit from the time of diagnosis of cancer and enrollment. - Eligible regardless of personal history of cancer Exclusion Criteria include: Triple Negative Breast Cancer -Patient is not within five years of diagnosis Germline mutation Carriers: -Patient only carries a HBOC mutation that is classified as "polymorphism" of "favor polymorphism"



Primary Contact:

Principal Investigator
Priyanka Sharma, MD
The University of Kansas Medical Center

Kelsey Schwensen
Phone: (913) 588-6079
Email: kschwensen@kumc.edu

Backup Contact:


Location Contact:

Overland Park, Kansas 66209
United States

Amy Nelson
Phone: 913-498-7892

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: September 28, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.